Malhotra Anjli, Gupta Rajeev, Mahajan Shveta
Department of Medicine, SGRD Institute of Medical Sciences and Research, Amritsar, Punjab, India.
Dental Surgeon, PHC Lakhanpur, Directorate of Health Services Jammu UT (J&K), India.
Rep Pract Oncol Radiother. 2023 Aug 28;28(4):463-467. doi: 10.5603/RPOR.a2023.0055. eCollection 2023.
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell disorder. It is associated with acquired genetic changes in the hematopoietic stem cells in the form of BCR-ABL fusion gene also known as Philadelphia chromosome.
We prospectively studied thyroid function at baseline and at 6 months of imatinib treatment in 26 newly diagnosed BCR-ABL positive CML patients.
The thyroid-stimulating hormone (TSH) levels increased significantly from baseline (3.20 ± 0.978 mIU/L . 3.724 ± 1.726 mIU/L, p < 0.05) after 6 months of treatment, 88.4% of the patients remained euthyroid. Only 2 patients had subclinical hypothyroidism, 1 had hypothyroidism after 6 months of tyrosine kinase inhibitors (TKI) therapy.
Imatinib did not have any significant effect on thyroid function in CML patients in this study.
慢性粒细胞白血病（CML）是一种造血干细胞疾病。它与造血干细胞中获得性基因改变有关，表现为BCR-ABL融合基因，也称为费城染色体。
我们前瞻性地研究了26例新诊断的BCR-ABL阳性CML患者在基线时以及伊马替尼治疗6个月时的甲状腺功能。
治疗6个月后，促甲状腺激素（TSH）水平从基线时的（3.20±0.978 mIU/L）显著升高至（3.724±1.726 mIU/L，p<0.05），88.4%的患者仍处于甲状腺功能正常状态。仅2例患者有亚临床甲状腺功能减退，1例在酪氨酸激酶抑制剂（TKI）治疗6个月后出现甲状腺功能减退。
在本研究中，伊马替尼对CML患者的甲状腺功能没有显著影响。
